source
- Novo Nordisk launches Phase 3 trial of lower maintenance doses of oral Wegovy for obesityNovo Nordisk has begun a Phase 3, placebo-controlled study called OASIS 5 to evaluate two lower oral doses of its GLP-1 weight-loss drug Wegovy (semaglutide) in people who are obese or overweight.…
- FDA clears Vitestro's Aletta, first robotic blood draw device for U.S. clinicsThe U.S. Food and Drug Administration has granted clearance to Vitestro's Aletta, making it the first standalone robotic system approved to draw blood without direct human handling. Aletta can per…